Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.
Kavanagh D, McGlasson S, Jury A, Williams J, Scolding N, Bellamy C, Gunther C, Ritchie D, Gale DP, Kanwar YS, Challis R, Buist H, Overell J, Weller B, Flossmann O, Blunden M, Meyer EP, Krucker T, Evans SJ, Campbell IL, Jackson AP, Chandran S, Hunt DP. Kavanagh D, et al. Among authors: overell j. Blood. 2016 Dec 15;128(24):2824-2833. doi: 10.1182/blood-2016-05-715987. Epub 2016 Sep 23. Blood. 2016. PMID: 27663672 Free PMC article.
Thrombotic microangiopathy associated with interferon beta.
Hunt D, Kavanagh D, Drummond I, Weller B, Bellamy C, Overell J, Evans S, Jackson A, Chandran S. Hunt D, et al. Among authors: overell j. N Engl J Med. 2014 Mar 27;370(13):1270-1. doi: 10.1056/NEJMc1316118. N Engl J Med. 2014. PMID: 24670186 Free PMC article. No abstract available.
MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosis.
York EN, Martin SJ, Meijboom R, Thrippleton MJ, Bastin ME, Carter E, Overell J, Connick P, Chandran S, Waldman AD, Hunt DPJ; Future-MS Consortium. York EN, et al. Among authors: overell j. Brain Commun. 2021 Nov 3;3(4):fcab249. doi: 10.1093/braincomms/fcab249. eCollection 2021. Brain Commun. 2021. PMID: 34877533 Free PMC article.
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.
Brown JWL, Cunniffe NG, Prados F, Kanber B, Jones JL, Needham E, Georgieva Z, Rog D, Pearson OR, Overell J, MacManus D, Samson RS, Stutters J, Ffrench-Constant C, Gandini Wheeler-Kingshott CAM, Moran C, Flynn PD, Michell AW, Franklin RJM, Chandran S, Altmann DR, Chard DT, Connick P, Coles AJ. Brown JWL, et al. Among authors: overell j. Lancet Neurol. 2021 Sep;20(9):709-720. doi: 10.1016/S1474-4422(21)00179-4. Lancet Neurol. 2021. PMID: 34418398 Clinical Trial.
A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe.
Giovannoni G, de Jong B, Derfuss T, Izquierdo G, Mazibrada G, Molyneux P, Nicholas R, Overell J, Ziemssen T, Juliusson G. Giovannoni G, et al. Among authors: overell j. Mult Scler Relat Disord. 2015 Jan;4(1):83-4. doi: 10.1016/j.msard.2014.09.215. Epub 2014 Oct 13. Mult Scler Relat Disord. 2015. PMID: 25787058 No abstract available.
Outcome after conservative management or intervention for unruptured brain arteriovenous malformations.
Al-Shahi Salman R, White PM, Counsell CE, du Plessis J, van Beijnum J, Josephson CB, Wilkinson T, Wedderburn CJ, Chandy Z, St George EJ, Sellar RJ, Warlow CP; Scottish Audit of Intracranial Vascular Malformations Collaborators. Al-Shahi Salman R, et al. JAMA. 2014 Apr 23-30;311(16):1661-9. doi: 10.1001/jama.2014.3200. JAMA. 2014. PMID: 24756516 Free article.
Diagnosis and management of multiple sclerosis: MRI in clinical practice.
Tomassini V, Sinclair A, Sawlani V, Overell J, Pearson OR, Hall J, Guadagno J. Tomassini V, et al. Among authors: overell j. J Neurol. 2020 Oct;267(10):2917-2925. doi: 10.1007/s00415-020-09930-0. Epub 2020 May 29. J Neurol. 2020. PMID: 32472179 Free PMC article.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
Giovannoni G, Kappos L, de Seze J, Hauser SL, Overell J, Koendgen H, Manfrini M, Wang Q, Wolinsky JS. Giovannoni G, et al. Among authors: overell j. Eur J Neurol. 2022 Apr;29(4):1238-1242. doi: 10.1111/ene.14823. Epub 2021 May 5. Eur J Neurol. 2022. PMID: 33724637 Free PMC article. Clinical Trial.
45 results